Free Trial

Stryker (SYK) Competitors

Stryker logo
$390.80 -0.66 (-0.17%)
Closing price 03:59 PM Eastern
Extended Trading
$393.28 +2.47 (+0.63%)
As of 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SYK vs. CSQ, ISRG, BSX, CAH, COR, DVA, MDT, ZBH, ABT, and BDX

Should you be buying Stryker stock or one of its competitors? The main competitors of Stryker include Calamos Strategic Total Return Fund (CSQ), Intuitive Surgical (ISRG), Boston Scientific (BSX), Cardinal Health (CAH), Cencora (COR), DaVita (DVA), Medtronic (MDT), Zimmer Biomet (ZBH), Abbott Laboratories (ABT), and Becton, Dickinson and Company (BDX).

Stryker vs. Its Competitors

Stryker (NYSE:SYK) and Calamos Strategic Total Return Fund (NASDAQ:CSQ) are related companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Stryker presently has a consensus target price of $428.55, indicating a potential upside of 9.66%. Given Stryker's stronger consensus rating and higher probable upside, analysts clearly believe Stryker is more favorable than Calamos Strategic Total Return Fund.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stryker
0 Sell rating(s)
4 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
2.79
Calamos Strategic Total Return Fund
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Stryker has higher revenue and earnings than Calamos Strategic Total Return Fund.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$22.60B6.60$2.99B$7.4052.81
Calamos Strategic Total Return Fund$280.21MN/AN/AN/AN/A

In the previous week, Stryker had 42 more articles in the media than Calamos Strategic Total Return Fund. MarketBeat recorded 43 mentions for Stryker and 1 mentions for Calamos Strategic Total Return Fund. Calamos Strategic Total Return Fund's average media sentiment score of 1.89 beat Stryker's score of 1.41 indicating that Calamos Strategic Total Return Fund is being referred to more favorably in the news media.

Company Overall Sentiment
Stryker Positive
Calamos Strategic Total Return Fund Very Positive

77.1% of Stryker shares are owned by institutional investors. 5.2% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Stryker pays an annual dividend of $3.36 per share and has a dividend yield of 0.9%. Calamos Strategic Total Return Fund pays an annual dividend of $1.23 per share and has a dividend yield of 6.8%. Stryker pays out 45.4% of its earnings in the form of a dividend. Stryker has increased its dividend for 32 consecutive years.

Stryker has a net margin of 12.31% compared to Calamos Strategic Total Return Fund's net margin of 0.00%. Stryker's return on equity of 23.74% beat Calamos Strategic Total Return Fund's return on equity.

Company Net Margins Return on Equity Return on Assets
Stryker12.31% 23.74% 11.25%
Calamos Strategic Total Return Fund N/A N/A N/A

Summary

Stryker beats Calamos Strategic Total Return Fund on 11 of the 14 factors compared between the two stocks.

Get Stryker News Delivered to You Automatically

Sign up to receive the latest news and ratings for SYK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SYK vs. The Competition

MetricStrykerMED PRODUCTS IndustryMedical SectorNYSE Exchange
Market Cap$149.42B$10.37B$5.62B$20.84B
Dividend Yield0.86%2.09%4.25%3.65%
P/E Ratio52.8116.6928.5727.17
Price / Sales6.6029.09424.2148.14
Price / Cash25.9522.6736.0222.28
Price / Book7.223.598.134.56
Net Income$2.99B$233.40M$3.24B$995.22M
7 Day Performance0.30%-1.64%2.03%-0.86%
1 Month Performance3.66%2.77%8.29%4.16%
1 Year Performance18.94%-17.92%28.40%8.88%

Stryker Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SYK
Stryker
4.4423 of 5 stars
$390.80
-0.2%
$428.55
+9.7%
+15.3%$149.42B$22.60B52.8153,000Positive News
Analyst Forecast
CSQ
Calamos Strategic Total Return Fund
N/A$18.25
-1.0%
N/A+5.6%$0.00$280.21M0.00N/APositive News
ISRG
Intuitive Surgical
4.6974 of 5 stars
$533.93
-1.9%
$588.95
+10.3%
+16.3%$191.36B$8.35B78.2815,638Positive News
Upcoming Earnings
Analyst Forecast
BSX
Boston Scientific
4.6044 of 5 stars
$103.48
-0.8%
$116.09
+12.2%
+34.4%$153.09B$16.75B75.5353,000
CAH
Cardinal Health
4.8724 of 5 stars
$166.47
+0.9%
$157.43
-5.4%
+71.8%$39.73B$226.83B25.9748,900Positive News
COR
Cencora
4.4805 of 5 stars
$299.63
+1.1%
$306.33
+2.2%
+33.4%$58.07B$293.96B34.7646,000Positive News
DVA
DaVita
4.4197 of 5 stars
$142.21
-0.2%
$164.50
+15.7%
+1.3%$10.74B$12.82B14.0976,000Positive News
MDT
Medtronic
4.558 of 5 stars
$87.52
-1.0%
$97.87
+11.8%
+15.1%$112.25B$33.54B24.1895,000Positive News
Analyst Forecast
ZBH
Zimmer Biomet
4.9407 of 5 stars
$92.26
-1.5%
$111.33
+20.7%
-13.7%$18.25B$7.68B20.4117,000News Coverage
Analyst Upgrade
Gap Up
ABT
Abbott Laboratories
4.9489 of 5 stars
$133.04
-1.0%
$142.61
+7.2%
+26.7%$231.47B$41.95B17.26114,000Upcoming Earnings
Analyst Forecast
BDX
Becton, Dickinson and Company
4.8191 of 5 stars
$172.96
-1.8%
$219.22
+26.7%
-22.7%$49.57B$20.18B33.0174,000Positive News
Analyst Revision

Related Companies and Tools


This page (NYSE:SYK) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners